Ipilimumab-induced Perforating Colitis
نویسندگان
چکیده
منابع مشابه
Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
A 56 year old man presenting with stage III melanoma was treated with ipilimumab therapy. After his second cycle of ipilimumab he developed severe abdominal cramping and non-bloody diarrhea. Colonoscopy revealed diffuse moderate inflammation (erosions, erythema, granularity, loss of vascularity) from transverse colon to the rectum (Fig. 1). Biopsy results revealed colonic mucosa with patchy, ly...
متن کاملIpilimumab-Induced Enteritis without Colitis: A New Challenge
INTRODUCTION Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma. It was the first therapy shown to prolong survival in a large, randomized clinical trial. However, immune-related adverse events are common and can be severe. Enterocolitis is a common adverse event with ipilimumab, but enteritis without...
متن کاملInfliximab for IPILIMUMAB-Related Colitis-Letter.
Ipilimumab, an anticytotoxic T-lymphocyte–associated protein (CTLA)-4 antibody, was approved in 2011 by the FDA for the treatment of advanced melanoma (1, 2). Our study aimed to evaluate the impact of immunosuppressants used for the treatment of immune-related adverse events (irAE) on outcome of patients treated with ipilimumab. We retrospectively evaluated 113 patients with advanced melanoma a...
متن کاملInfectious Colitis Associated With Ipilimumab Therapy
Ipilimumab is a monoclonal antibody against cytotoxic T lymphocyte-associated molecule-4 and is thought to promote anti-tumor activity by enhancing cell mediated immunity. It is one of the few therapies shown to improve overall survival in metastatic melanoma. Given its mechanism of action, the drug is associated with significant immune-related adverse events with the gastrointestinal system be...
متن کاملIpilimumab induced digital vasculitis
BACKGROUND Immune check point inhibitors (ICIs) have emerged as a new therapeutic paradigm for a variety of malignancies including metastatic melanoma. As the use of ICIs expand, immune-mediated adverse events are becoming a common occurrence. CASE PRESENTATION We describe the first reported patient with small vessel vasculitis, manifested by digital ischemia, following treatment with high do...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Gastroenterology
سال: 2013
ISSN: 0192-0790
DOI: 10.1097/mcg.0b013e31828f1d51